Scott analyzes the implications of the FDA ending compounded GLP-1 weight loss drugs, which have provided a cheaper alternative to official channels for the past three years, and examines various responses from both compounding pharmacies and pharmaceutical companies. Longer summary

Scott discusses the upcoming end to compounded GLP-1 weight loss drugs in the US, as the FDA declares the shortage over. He explains how for the past three years, compounding pharmacies have provided these drugs at $200/month compared to the official $1000/month price, helping about 2 million Americans. The post explores various strategies companies are using to try to continue providing cheaper alternatives, and how pharmaceutical companies are responding with their own direct-to-consumer models. Scott concludes by noting how this experiment in semi-free-market medicine has shown that a less regulated supply chain can work effectively. Shorter summary

Scott Alexander examines how compounding pharmacies are producing cheaper versions of GLP-1 agonist drugs, exploring the economics, safety, and future implications of this practice. Longer summary

Scott Alexander discusses the 'compounding loophole' that allows compounding pharmacies to produce cheaper versions of GLP-1 agonist drugs like semaglutide (Ozempic). He explains how these pharmacies operate, the cost differences, safety concerns, and potential future implications. The post covers the legal basis for this practice during drug shortages, the impact on drug manufacturers like Novo Nordisk, and speculates on what might happen when the shortage ends. Scott also touches on the broader implications for drug pricing and availability. Shorter summary